KR880009020A - 신규 치료법 - Google Patents

신규 치료법 Download PDF

Info

Publication number
KR880009020A
KR880009020A KR1019880000325A KR880000325A KR880009020A KR 880009020 A KR880009020 A KR 880009020A KR 1019880000325 A KR1019880000325 A KR 1019880000325A KR 880000325 A KR880000325 A KR 880000325A KR 880009020 A KR880009020 A KR 880009020A
Authority
KR
South Korea
Prior art keywords
hydrogen
compound
alkoxy
group
general formula
Prior art date
Application number
KR1019880000325A
Other languages
English (en)
Inventor
존 생거 가레스
엘리자베스 마아 헬렌
Original Assignee
원본미기재
비이참 그루우프 피이엘시이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 비이참 그루우프 피이엘시이 filed Critical 원본미기재
Publication of KR880009020A publication Critical patent/KR880009020A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Polarising Elements (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Processing Of Meat And Fish (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Steroid Compounds (AREA)

Abstract

내용 없음.

Description

신규 치료법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (7)

  1. 하기 일반구조식 (I) 화합물 또는 제약학적으로 허용가능한 그의 염 및 제약학적으로 허용가능한 담체를 포함하는 내장통 치료에 사용하기 위한 제약학적 조성물.
    X-CO-Y-Z (I)
    상기식에서, X는 하기 일반구조식(a),(b),(c),(d), 또는 (e)의 기이고
    상기식에서 Ra내지 Re는 수소, 할로겐 또는 히드록시로부터 선택되며 R1은 수소이고 R2는 수소 또는 C1-4알킬이며 ; 또는 R1과 R2가 함께 결합을 형성하고 ; R3내지 R7은 독립적으로 수소 또는 C1-6알킬이고 ; R1이 수소일때 R4는 R2와 함께 C2-7폴리메틸렌일 수 있으며 ; R8은 C1-6알콕시이며 ; R9은 수소이며 ; R10은 아미노 또는 C1-7알카노일아미노이며 ; R11은 할로 또는 C1-6알킬티오이며 ; 또는 R8은 수소이며 ; R9은 할로 C1-6알콕시 ; R10은 수소 또는 C1-6알콕시이며 ; R11은 할로, C1-6알킬이며 ; L은 CH 또는 N이며 ; Y는 NH 또는 0이며 단, X가 (e)이고 R8이 C1-7알콕시일때 Y는 NH이며 ; Z는 하기 일반구조식(f),(g) 또는 (h)의 기이고여기서 n은 2 또는 3이며 ; p와 q는 독립적으로 1 내지 3이며 ; R12또는 R13은 메틸 또는 에틸이다.
  2. 제1항에 있어서, X가 제1항에서 정의한 하부 일반구조식 (a)의 기이고, R1과 R3이 모두 수소이고 R2와 R4가 모두 메틸기이거나 또는 결합되어 C2-7폴리메틸렌을 형성하고 또는 R2와 R4중 하나는 수소이고 다른 것은 에틸 또는 n- 또는 이소-프로필인 조성물.
  3. 제1항에 있어서, X가 제1항에서 정의한 하부-일반구조식 (b)의 기이고, R5가 수소 또는 메틸 또는 에틸기인 조성물.
  4. 제1항에 있어서, Z가 제1항에서 정의한 하부-일반구조식 (f)의 기이고 n이 2 또는 3인 조성물.
  5. 제1항에 있어서, 일반구조식 (I) 화합물이 N-(엔도-9-메틸-9-아자비시클로-[3,3,1]논-3-일)-1-메틸-인다졸-3-카르복스아미드 또는 제약학적으로 허용가능한 그의 염인 조성물.
  6. 제1항에 있어서, 일반구조식 (I) 화합물이 2-메톡시-인돌-3-일 카르복실산 (엔도-8-아자비시클로[3,2,1]옥트-3-일)에스테르, 또는 제약학적으로 허용가능한 그의 염인 조성물.
  7. 제1항에 있어서, 일반구조식 (I) 화합물이 엔도-N-(8-메틸-8-아자비시클로 3,2,1 옥트-3-일)-2,3-디히드로-3,3-디메틸인돌-1-카르복스아미드인 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019880000325A 1987-01-19 1988-01-18 신규 치료법 KR880009020A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB878701022A GB8701022D0 (en) 1987-01-19 1987-01-19 Treatment
GB8701022 1987-01-19

Publications (1)

Publication Number Publication Date
KR880009020A true KR880009020A (ko) 1988-09-13

Family

ID=10610829

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019880000325A KR880009020A (ko) 1987-01-19 1988-01-18 신규 치료법

Country Status (12)

Country Link
US (3) US4845092A (ko)
EP (1) EP0279512B1 (ko)
JP (1) JP2584266B2 (ko)
KR (1) KR880009020A (ko)
AT (1) ATE135911T1 (ko)
AU (1) AU608276B2 (ko)
DE (1) DE3855144T2 (ko)
DK (1) DK20388A (ko)
ES (1) ES2085259T3 (ko)
GB (1) GB8701022D0 (ko)
GR (1) GR3019447T3 (ko)
ZA (1) ZA88266B (ko)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2828653B2 (ja) * 1989-04-13 1998-11-25 東ソー株式会社 接着性の改良されたポリフェニレンスルフィド樹脂組成物
IE913621A1 (en) * 1990-10-17 1992-04-22 Beecham Group Plc Novel treatment
HU211081B (en) * 1990-12-18 1995-10-30 Sandoz Ag Process for producing indole derivatives as serotonin antagonists and pharmaceutical compositions containing the same
GB9214184D0 (en) * 1992-07-03 1992-08-12 Smithkline Beecham Plc Pharmaceuticals
US5399562A (en) * 1994-02-04 1995-03-21 G. D. Searle & Co. Indolones useful as serotonergic agents
GB9721139D0 (en) 1997-10-07 1997-12-03 Glaxo Group Ltd Medicaments
WO2000048581A2 (en) * 1999-02-18 2000-08-24 Novartis Ag Use of 5-ht3 receptor antagonists for treating musculoeskeletal diseases
US20040048874A1 (en) * 2001-05-22 2004-03-11 Bardsley Hazel Judith New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine
GB0216027D0 (en) * 2002-07-10 2002-08-21 Arachnova Therapeutics Ltd New therapeutic use
AR036041A1 (es) 2001-06-12 2004-08-04 Upjohn Co Compuestos aromaticos heterociclicos sustituidos con quinuclidina y composiciones farmaceuticas que los contienen
AR036040A1 (es) 2001-06-12 2004-08-04 Upjohn Co Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen
JP2005527472A (ja) * 2001-09-12 2005-09-15 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 疾患治療のための置換された７−アザ［２．２．１］ビシクロヘプタン
DK1432707T3 (da) 2001-10-02 2012-06-11 Pharmacia & Upjohn Co Llc Azabicyklisk-substituerede kondenserede heteroarylforbindelser til behandling af sygdomme
US6849620B2 (en) 2001-10-26 2005-02-01 Pfizer Inc N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease
US6951868B2 (en) 2001-11-09 2005-10-04 Pfizer Inc. Azabicyclic-phenyl-fused-heterocyclic compounds for treatment of disease
US6894042B2 (en) * 2002-02-19 2005-05-17 Pharmacia & Upjohn Company Azabicyclic compounds for the treatment of disease
CA2476681A1 (en) * 2002-02-19 2003-08-28 Bruce N. Rogers Fused bicyclic-n-bridged-heteroaromatic carboxamides for the treatment of disease
AU2003276919B2 (en) 2002-09-25 2013-05-16 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof
JP2006506395A (ja) * 2002-11-01 2006-02-23 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー ＣＮＳ疾患の治療のための、α７ニコチンアゴニスト活性及び５ＨＴ３アンタゴニスト活性を有する化合物
EP1567163B1 (en) * 2003-01-13 2007-04-11 Dynogen Pharmaceuticals Inc. Method of treating nausea, vomiting, retching or any combination thereof
EP1558081A4 (en) * 2003-01-13 2006-06-14 Dynogen Pharmaceuticals Inc METHOD OF TREATING FUNCTIONAL INTESTINAL DISORDERS
WO2005041988A1 (en) * 2003-10-22 2005-05-12 University Of Florida Method and composition for pain amelioration
RS20060391A (en) 2003-12-22 2008-11-28 Memory Pharmaceuticals Corporation, Indoles, 1h-indazoles, 1,2-benzisoxazoles, and 1,2- benzisothiazoles, and preparation and uses thereof
TW200533348A (en) * 2004-02-18 2005-10-16 Theravance Inc Indazole-carboxamide compounds as 5-ht4 receptor agonists
US7820690B2 (en) 2004-03-19 2010-10-26 Solvay Pharmaceuticals Gmbh Method of treating or inhibiting a non-digestive tract derived abdominal disorder associated with pain using a 5-HT, receptor antagonist
WO2005089732A1 (en) * 2004-03-19 2005-09-29 Solvay Pharmaceuticals Gmbh Use of a 5-ht3 receptor antagonist for the manufacture of a medicament for the treatment of non-digestive tract derived abdominal disorders associated with pain
CN103724343A (zh) 2004-03-25 2014-04-16 记忆药物公司 吲唑、苯并噻唑、苯并异噻唑、苯并异噁唑及其制备和用途
US7728006B2 (en) * 2004-04-07 2010-06-01 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
US8309575B2 (en) 2004-04-07 2012-11-13 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
TWI351282B (en) 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
JP2007534692A (ja) 2004-04-22 2007-11-29 メモリー・ファーマシューティカルズ・コーポレイション インドール、１ｈ−インダゾール、１，２−ベンズイソキサゾール、１，２−ベンゾイソチアゾール、ならびにその調製および使用
RU2386633C2 (ru) 2004-05-07 2010-04-20 Мемори Фармасьютиклз Корпорейшн 1h-индазолы, бензотиазолы, 1, 2-бензоизоксазолы, 1, 2-бензоизотиазолы и хромоны и их получение и применения
JP5042028B2 (ja) * 2004-11-05 2012-10-03 セラヴァンス， インコーポレーテッド キノリノン−カルボキサミド化合物
ATE441646T1 (de) * 2004-11-05 2009-09-15 Theravance Inc 5-ht4-rezeptoragonistenverbindungen
CA2589363A1 (en) * 2004-12-13 2006-06-22 Eli Lilly And Company Spiro derivatives as lipoxygenase inhibitors
US7419989B2 (en) * 2004-12-22 2008-09-02 Theravance, Inc. Indazole-carboxamide compounds
CA2591817A1 (en) * 2004-12-22 2006-06-29 Memory Pharmaceuticals Corporation Nicotinic alpha-7 receptor ligands and preparation and uses thereof
US20060160905A1 (en) * 2005-01-18 2006-07-20 Bergeron Raymond J Jr Compositions and methods for inhibiting pain
EP1871772B1 (en) * 2005-03-02 2014-09-10 Theravance, Inc. Quinolinone compounds as 5-ht4 receptor agonists
WO2006105117A2 (en) * 2005-03-28 2006-10-05 Dynogen Pharmaceuticals, Inc. Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
US8106066B2 (en) 2005-09-23 2012-01-31 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1220141A (en) * 1981-06-13 1987-04-07 John R. Fozard Treatment of migraine with tropyl benzoate derivatives
FR2531083B1 (fr) * 1982-06-29 1986-11-28 Sandoz Sa Nouveaux derives de la piperidine, leur preparation et leur utilisation comme medicaments
JPS5936675A (ja) * 1982-07-13 1984-02-28 サンド・アクチエンゲゼルシヤフト 二環性複素環式カルボン酸アザビシクロアルキルエステルまたはアミド
FR2557110B1 (fr) * 1983-12-23 1989-11-24 Sandoz Sa Nouveaux derives d'amines cycliques, leur preparation et leur utilisation comme medicaments
DE3587151T2 (de) * 1984-12-20 1993-07-15 Sandoz Ag Behandlung von gastrointestinalkrankheiten durch anwendung von 5-ht3-antagonisten.
DE3689974T2 (de) * 1985-03-14 1994-11-03 Beecham Group Plc Arzneimittel zur Behandlung von Emesis.
GB8510752D0 (en) * 1985-04-27 1985-06-05 Beecham Group Plc Compounds
GB8525913D0 (en) * 1985-10-21 1985-11-27 Beecham Group Plc Compounds
EP0498466B1 (en) * 1985-04-27 2002-07-24 F. Hoffmann-La Roche Ag Indazole-3-carboxamide and -3-carboxylic acid derivatives
EP0220011A3 (en) * 1985-10-12 1990-01-03 Beecham Group Plc Use of azabicloalkylbenzamides in the treatment of gastrointestinal motility disorders, migraine, emesis, cluster headaches, trigeminal neuralgia and arrhythmia
DE3687980T2 (de) * 1986-01-07 1993-06-17 Beecham Group Plc Indolderivate mit einer azabicyclischen seitenkette, verfahren zu ihrer herstellung, zwischenprodukte und pharmazeutische zusammensetzungen.
EP0235878A3 (en) * 1986-01-16 1989-06-14 Beecham Group Plc Novel compounds

Also Published As

Publication number Publication date
US4942160A (en) 1990-07-17
DE3855144T2 (de) 1996-08-22
US4845092A (en) 1989-07-04
US5063231A (en) 1991-11-05
DK20388A (da) 1988-07-20
ES2085259T3 (es) 1996-06-01
DK20388D0 (da) 1988-01-18
JPS63215627A (ja) 1988-09-08
JP2584266B2 (ja) 1997-02-26
GR3019447T3 (en) 1996-06-30
DE3855144D1 (de) 1996-05-02
ZA88266B (en) 1988-11-30
AU1035588A (en) 1988-07-21
GB8701022D0 (en) 1987-02-18
ATE135911T1 (de) 1996-04-15
EP0279512A3 (en) 1992-09-16
EP0279512A2 (en) 1988-08-24
AU608276B2 (en) 1991-03-28
EP0279512B1 (en) 1996-03-27

Similar Documents

Publication Publication Date Title
KR880009020A (ko) 신규 치료법
KR880012526A (ko) l-페닐-3-나프탈레닐옥시프로판아민
KR910004582A (ko) 티아졸 유도체, 이의 제조방법 및 이를 함유하는 약학조성물
DE68914292D1 (de) Zusammensetzung zur Behandlung von ischämischen Störungen in Organen.
KR880000400A (ko) 융합된 사이클릭 아제핀-2-온 유도체 및 그의 제조방법
KR940005274A (ko) 쇼그렌(Sjoegren)증후군 치료제
SE8604950L (sv) Demensforbettrande och terapeutiska medel
DE68928174D1 (de) Verfahren zur Herstellung von Cephemderivaten
ES8403872A1 (es) Un metodo para preparar compuesto de piridilo.
KR880000432A (ko) 4(3H)-옥소-5,6,7,8-테트라히드로피리도-2,3-d 피리미딘 유도체
ES2058085T3 (es) Composicion anticonvulsivante que contiene un derivado de aminoacido, y utilizacion de dicho derivado de aminoacido.
KR920004402A (ko) 신규 퀴놀린 카르복실산 유도체, 상기 화합물 함유 항균제 및 상기 화합물 제조 방법
KR890003755A (ko) 7- (2- 메틸- 4- 아미노피롤리디닐)나프티리딘 및 퀴놀린 화합물
KR870004992A (ko) 세팔로스포린 유도체의 제조방법
KR950702566A (ko) 사슬형 아미딘기를 포함하는 디포스폰산 유도체, 그것의 제조방법 및 그것을 포함하는 의약 조성물(novel acyclic amidine-group-containing diphosphonic acid derivatives, process for producing them and medicaments containing these compounds)
KR910006292A (ko) 방향족 산의 n-아자비시클로 [3.3.0] 옥탄 아미드
KR890003762A (ko) 10.11-디하이드로-5H- 디벤조[a,d]사이클로헵텐-5,10-이민의 폴리하이드로 유도체
SI9300150B (sl) Kristalne oblike endo-2,3-dihidro-N-(8-metil-8-azabicilo/3.2.1./okt-3-il)-2-okso-1H- benzimidazol-1-karboksamid hidroklorid monohidrata in endo-3-etil-2,3-dihidro-N-(8-metil-8-azabiciklo/3.2.1/okt-3-il)-2-okso- 1H-benzimidazol-1-karboksamid hidroklorid monohidrata
KR910700236A (ko) 치환된 3-아자비사이클로[3,1,1]헵탄, 이의 제조방법 및 이의 용도
KR960703924A (ko) 항바이러스제로서 신규한 벤조티오펜 유사체(Novel Benzothiophene Analogs as Antiviral Agents)
KR880701230A (ko) 항콜린 작동성 화합물, 약학 조성물 및 치료방법
IT1205114B (it) 2-selenometil-1,4-diidropiridine,procedimento per la loro preparazione e composizioni farmaceutiche che le contengono
KR890005123A (ko) 세펨 화합물 및 이의 제조방법
KR940014411A (ko) 신규 세팔로스포린계 항생제(v)
ES8103082A1 (es) Procedimiento de preparacion de nuevos derivados pirido (3,4-e)-as-triazinos acilados y de sus sales de acicion aci-da de los mismos

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid